STOCKS TELEGRAPH

Tag: RGLS

  • New Developments Related to RGLS8429: Regulus Therapeutics Inc. (RGLS) Soars High After Hours

    On January 20, Regulus Therapeutics Inc. (RGLS) announced the successful completion of the pre-IND meeting for RGLS8429 with the FDA. Consequently, the stock advanced further in the after hours.

    During the regular session, the stock fluctuated between $0.2500 and $0.2421 at 1.27 million shares. RGLS closed the session with a mild gain of 2.04% at $0.2449. Following the announcement, the stock added a further 6.12% at $0.2599 in the after-hours session.

    The clinical-stage biopharmaceutical company, Regulus Therapeutics Inc. has a market capitalization of $35.03 million. Currently, the company has 145.97 million shares outstanding in the market.

    RGLS’ Pre-IND Meeting

    As per the announcement, the pre-IND meeting with the FDA regarding RGLS8429 as a potential treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The reason for the meeting was the FDA’s input on the pre-clinical, clinical, and regulatory matters of RGLS’ next-generation compound. Earlier this week, the company had received the formal minutes from the meeting.

    Moreover, the meeting resulted in the FDA’s agreement with an overall agreement with the Phase 1 trial design of RGLS8429 along with its length and the proposed starting dose. Therefore, the company is on track for the submission of the IND application in Q2 of 2022 for clearance of Phase 1 trial commencement.

    Phase 1 Clinical Trial of RGLS8429

    The phase 1 clinical study of the product will have two parts:

    Part 1

    Part 1 will be a single-ascending dose (SAD) study for evaluating safety and tolerability for pharmacokinetics characterization in healthy volunteers. Further, 32 volunteers will be randomized to RGLS8429 or placebo in the part one cohort.

    Part 2

    Part 2 will be a multiple-ascending dose (MAD) study in ADPKD adult patients. Furthermore, it will evaluate the safety and tolerability of the product for pharmacokinetics characterization and the dose-response. 36 patients will be randomized in the cohorts of this part.

    In addition, the updated clinical plans encompass extending dosing to three months in each cohort of ADPKD patients.

    RGLS Financial Analysis

    On November 10, the company declared its financial results for the third quarter of 2021.

    In the third quarter of 2021, RGLS incurred a net loss of $8.6 million, against $1.5 million in the year-ago period. Resultantly, the net loss per basic and diluted share was $0.10 in Q3 of 2021 and $0.04 in Q3 of 2020.

    Additionally, the company ended the quarter with cash and cash equivalents of $35.8 million.

  • Market Movers: What changed for these 37 stocks while you were sleeping

    Market Movers: What changed for these 37 stocks while you were sleeping

    Immutep Limited (NASDAQ: IMMP) shares are trading down -26.19% at $4.2 at the time of writing after reporting that its Chinese partner, EOC Pharma will begin a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. Company’s 52-week ranged between $0.53 to $3.10. Analysts have a consensus price target of $7.75.
    SELLAS Life Sciences Group Inc. (SLS) stock plunged -24.18% to $13.39 in the pre-market trading. The most recent rating by Oppenheimer, on November 01, 2018, is an Outperform.
    Veru Inc. (VERU) tumbled over -11.89% at $5.26 in pre-market trading today. The firm recently declared that it has exclusively licensed phase 3 clinical stage targeted therapy for endocrine resistant metastatic breast cancer.
    Before the trading started on December 11, 2020, Professional Diversity Network Inc. (IPDN) is down -25.0% to reach $1.53. It has been trading in a 52-week range of $0.76 to $3.98.
    Neos Therapeutics Inc. (NEOS), a Drug Manufacturers – Specialty & Generic company, dropped about -16.36% at $0.6832 in pre-market trading Friday after announcing definitive merger agreement with Aytu BioScience, pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.
    Callon Petroleum Company (CPE) is down more than -0.53% at $15.0 in pre-market hours Friday December 11, 2020. The stock had jumped over 7.71% to $15.08 in the last trading session.
    C3.ai Inc. (AI) stock moved down -5.38 percent to $123.0 in the pre-market trading. The company lately declared the pricing of its initial public offering of 15,500,000 shares of its Class A common stock at a price of $42.00 per share.
    Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) shares are trading up 2.21% at $1.85 at the time of writing. Company’s 52-week ranged between $1.00 to $6.90. Analysts have a consensus price target of $14.
    Regulus Therapeutics Inc. (RGLS) stock plunged -9.92% to $1.09 in the pre-market trading. The healthcare company revealed closing of $19.4 million private placement of equity. The most recent rating by B. Riley FBR Inc., on March 28, 2018, is a Neutral.
    Range Resources Corporation (RRC) stock plunged -4.79% to $7.35 in the pre-market trading. The most recent rating by Stephens, on November 16, 2020, is an Overweight.
    Zedge Inc. (AMEX: ZDGE) shares are trading up 23.7% at $6.68 at the time of writing after reporting first fiscal quarter revenue growth of 85% and record overall quarterly financial results. Company’s 52-week ranged between $0.66 to $4.70. Analysts have a consensus price target of $3.
    Hennessy Capital Acquisition Corp. IV (HCAC), a Shell Companies company, dropped about -5.82% at $20.72 in pre-market trading Friday.
    Editas Medicine Inc. (EDIT) grew over 0.84% at $67.4 in pre-market trading today. The company recently publicized submission of IND application for EDIT-301 with the FDA.
    Greenwich LifeSciences Inc. (GLSI) is down more than -9.3% at $65.5 in pre-market hours Friday December 11, 2020 following the today’s announcement of poster presentation on its GP2 phase III clinical trial design for recurring breast cancer. The stock had jumped over 26.48% to $72.22 in the last trading session.
    Silver Spike Acquisition Corp. (SSPK) is down more than -2.78% at $14.0 in pre-market hours Friday December 11, 2020. The stock had jumped over 37.27% to $14.40 in the last trading session.
    Biocept Inc. (BIOC) stock plunged -3.07% to $5.68 in the pre-market trading after declaring results from a prospective study showing Target Selector™ was highly accurate in monitoring HER2 alterations in patients with metastatic breast cancer. The most recent rating by Chardan Capital Markets, on November 14, 2017, is a Buy.
    W&T Offshore Inc. (NYSE: WTI) shares are trading down -6.02% at $2.5 at the time of writing following the firm provided an operational update regarding fourth quarter 2020 production. Company’s 52-week ranged between $1.07 to $6.10.
    Before the trading started on December 11, 2020, Platinum Group Metals Ltd. (PLG) is up 1.93% to reach $5.27. It has been trading in a 52-week range of $0.86 to $5.20.
    Aytu BioScience Inc. (AYTU), a Biotechnology company, dropped about -24.72% at $6.12 in pre-market trading Friday after the company and Neos Therapeutics declared definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.
    Torchlight Energy Resources Inc. (TRCH) stock soared 13.78% to $0.7226 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.
    Before the trading started on December 11, 2020, Energy Fuels Inc. (UUUU) is up 1.64% to reach $3.1 following the announcement from the company that that its President and CEO Mark S. Chalmers will be presenting live at the 13th Annual LD Micro Main Event investor conference on Monday, December 14, 2020 at 11:40 AM (EST). It has been trading in a 52-week range of $0.78 to $2.99.
    Ashford Hospitality Trust Inc. (NYSE: AHT) shares are trading up 8.04% at $4.3 at the time of writing. Company’s 52-week ranged between $1.27 to $29.44.
    ClearOne Inc. (CLRO) stock plunged -7.2% to $2.45 in the pre-market trading after declaring that it has appointed Chromasound PLC, based in Budapest, Hungary, as its newest distribution partner. The most recent rating by Singular Research, on August 16, 2018, is a Buy – long-term.
    ReWalk Robotics Ltd. (NASDAQ: RWLK) shares are trading up 3.7% at $1.4 at the time of writing after revealing a contract with a German private health insurance company to allow all eligible beneficiaries with spinal cord injury (SCIs) to apply for the procurement of a ReWalk 6.0 exoskeleton system. Company’s 52-week ranged between $0.41 to $2.71. Analysts have a consensus price target of $1.50.
    Progenity Inc. (PROG) grew over 9.32% at $4.34 in pre-market trading today. The firm recently reported closing of the convertible senior notes offering and partial exercise of the Initial purchaser’s option to purchase additional notes.
    Boxlight Corporation (BOXL) is down more than -7.69% at $1.8 in pre-market hours Friday December 11, 2020. The stock had jumped over 17.47% to $1.95 in the last trading session.
    Lemonade Inc. (LMND), a Insurance – Property & Casualty company, rose about 0.7% at $100.4 in pre-market trading Friday. The company recently declared that residents of France can now get renters insurance instantly, anytime, and from any device – as well as file claims and get paid in seconds through the Lemonade app.
    ObsEva SA (OBSV) lost over -2.54% at $2.3 in pre-market trading Friday December 11, 2020 after announcing topline 52-week PRIMROSE 1 and 76-week PRIMROSE 2 results of Yselty, in development for the treatment of women with heavy menstrual bleeding due to uterine fibroids.
    Amplify Energy Corp. (AMPY) is down more than -27.33% at $1.09 in pre-market hours Friday December 11, 2020 following the commencement of an underwritten public offering of 8,548,485 shares of its common stock by certain of its stockholders which are affiliates of Fir Tree Capital Management L.P. The stock had jumped over 11.94% to $1.50 in the last trading session.
    Before the trading started on December 11, 2020, Hoth Therapeutics Inc. (HOTH) is up 0.54% to reach $1.85 after the firm revealed that it has received approval to commence phase 1b clinical trial of BioLexa for the treatment of Atopic Dermatitis in humans. It has been trading in a 52-week range of $1.60 to $7.25.
    RMG Acquisition Corp. (RMG) grew over 6.6% at $22.29 in pre-market trading today after declaring stockholder meeting Date of December 28, 2020.
    Marathon Patent Group Inc. (MARA) is down more than -10.34% at $4.68 in pre-market hours Friday December 11, 2020. The company recently stated that it has entered into a contract with Bitmain to purchase 10,000 Antminer S-19j Pro ASIC Miners. The stock had jumped over 9.21% to $5.22 in the last trading session.
    Before the trading started on December 11, 2020, Inseego Corp. (INSG) is up 7.26% to reach $13.15. The firm today reported that the it is expanding its global footprint in Japan with the launch of its industry-leading 5G MiFi® M2000 mobile hotspot. It has been trading in a 52-week range of $3.91 to $15.25.
    Entera Bio Ltd. (ENTX) tumbled over -7.56% at $1.1 in pre-market trading today after revealing FDA approval of IND application for EB613 – an oral human Parathyroid Hormone (1-34) for the treatment of Osteoporosis.
    OncoCyte Corporation (OCX) stock moved up 3.23 percent to $2.24 in the pre-market trading. The firm recently reported that it will host a key opinion leader (KOL) call on the Company’s proprietary DetermaRx™ and DetermaIO™ molecular tests for cancer treatment selection on Tuesday, December 15, 2020 at 11:00am Eastern Time.
    ZK International Group Co. Ltd. (ZKIN) lost over -4.98% at $2.1 in pre-market trading Friday December 11, 2020 after declaring that it signed a letter of intent with Tuopeng Industrial, a prominent construction and real estate company.
    Before the trading started on December 11, 2020, Arbutus Biopharma Corporation (ABUS) is up 15.8% to reach $4.25. It has been trading in a 52-week range of $0.88 to $9.02 following the declaration of additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

  • What changed for these 31 stocks in Pre Market Session

    What changed for these 31 stocks in Pre Market Session

    Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market under Nasdaq Rules. The most recent rating by Maxim Group, on January 08, 2020, is a Buy.
    Curis Inc. (CRIS), a Biotechnology company, dropped about -5.72% at $7.25 in pre-market trading Thursday after declaring the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.
    ZW Data Action Technologies Inc. (CNET) lost over -11.33% at $1.8 in pre-market trading Thursday December 10, 2020 after reporting the official opening of its first live streaming platform in Guangzhou, China.
    Genius Brands International Inc. (GNUS) is up more than 9.74% at $1.69 in pre-market hours Thursday December 10, 2020. The firm recently revealed that it will be presenting at the 13th Annual LD Micro investor conference on Tuesday, December 15th at 10:00 a.m. PST / 1:00 p.m. EST. The stock had dropped over -4.35% to $1.54 in the last trading session.
    Rocket Companies Inc. (RKT), a Mortgage Finance company, rose about 3.09% at $21.71 in pre-market trading Thursday following the release of Clear HOI platform from its subsidiary to mortgage lenders nationwide.
    Intec Pharma Ltd (NTEC) stock moved down -7.76 percent to $4.28 in the pre-market trading. Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma.
    Atossa Therapeutics Inc. (ATOS) gained over 2.31% at $0.8919 in pre-market trading Thursday December 10, 2020 after revealing cannabinoid research collaboration with GW Pharma.
    Nano Dimension Ltd. (NNDM) is up more than 2.25% at $6.82 in pre-market hours Thursday December 10, 2020 following the declaration from the company that it has closed the registered direct offering of 30,000,000 of the Company’s American Depositary Shares at a price of $6.00 per ADS. The stock had dropped over -6.06% to $6.67 in the last trading session.
    Before the trading started on December 10, 2020, Sorrento Therapeutics Inc. (SRNE) is down -2.44% to reach $8.01 following the FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). It has been trading in a 52-week range of $1.55 to $19.39.
    Genetic Technologies Limited (GENE) stock plunged -9.17% to $4.06 in the pre-market trading.
    Greenwich LifeSciences Inc. (GLSI) grew over 46.76% at $83.8 in pre-market trading today after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.
    Lipocine Inc. (LPCN), a Biotechnology company, dropped about -5.3% at $1.25 in pre-market trading Thursday after announcing that the U.S. Food and Drug Administration has granted tentative approval to TLANDO.
    SELLAS Life Sciences Group Inc. (SLS) stock moved up 51.8 percent to $9.7 in the pre-market trading. The biotechnology firm recently revealed exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China.
    Francesca’s Holdings Corporation (NASDAQ: FRAN) shares are trading down -10.68% at $2.51 at the time of writing after receiving court approval of “First Day” motions to support ongoing operations. Company’s 52-week ranged between $1.70 to $19.91. Analysts have a consensus price target of $2.50.
    Oncternal Therapeutics Inc. (ONCT) tumbled over -27.78% at $4.55 in pre-market trading today after announcing that the firm increased its previously declared bought deal to $75.0 million.
    Gran Tierra Energy Inc. (GTE) is down more than -2.83% at $0.35 in pre-market hours Thursday December 10, 2020. The company recently declared a financial update and the Company’s 2021 capital budget and production guidance. The stock had dropped over -5.68% to $0.36 in the last trading session.
    Before the trading started on December 10, 2020, Fisker Inc. (FSR) is down -4.04% to reach $16.15. The firm recently confirmed that it has signed agreements with Cox Automotive U.K. (“Cox”) and Rivus Fleet Solutions for delivery, servicing, fleet management and reselling programs in the United Kingdom. It has been trading in a 52-week range of $8.70 to $23.63.
    Immutep Limited (IMMP) stock soared 89.35% to $4.09 in the pre-market trading after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. The most recent rating by B. Riley FBR, on September 28, 2018, is a Buy.
    Remark Holdings Inc. (MARK), a Internet Content & Information company, rose about 3.09% at $1.67 in pre-market trading Thursday after reporting that Remark’s KanKan AI business successfully released its edge computing systems, the S and T Series Smart Boxes.
    Baidu Inc. (BIDU) gained over 2.42% at $155.26 in pre-market trading Thursday December 10, 2020. The firm recently released new intelligent vehicle solutions for automakers and several high-end intelligent driving products during the second Apollo Ecosystem Conference.
    Before the trading started on December 10, 2020, Editas Medicine Inc. (EDIT) is up 9.13% to reach $55.2 after reporting submission of IND application for EDIT-301 with the FDA. It has been trading in a 52-week range of $14.01 to $43.65.
    Artelo Biosciences Inc. (ARTL) stock plunged -2.47% to $0.66 in the pre-market trading. The healthcare firm recently declared that it has filed a composition of matter patent application directed to a new solid dosage formulation, including its method of use, with the UK Patent Office.
    AquaBounty Technologies Inc. (NASDAQ: AQB) shares are trading down -17.07% at $7.19 at the time of writing following the selection of Innovasea as the Recirculating Aquaculture Systems (“RAS”) technology provider for its planned 10,000 metric ton farm. Company’s 52-week ranged between $1.52 to $11.40. Analysts have a consensus price target of $5.
    Pluristem Therapeutics Inc. (PSTI) lost over -5.57% at $6.61 in pre-market trading Thursday December 10, 2020 after declaring DMC recommendation following interim analysis of its phase III CLI study.
    Before the trading started on December 10, 2020, Veru Inc. (VERU) is up 25.96% to reach $4.9 after reporting that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer. It has been trading in a 52-week range of $2.10 to $4.74.
    Uranium Energy Corp. (AMEX: UEC) shares are trading down -4.32% at $1.33 at the time of writing. Company’s 52-week ranged between $0.35 to $1.59. Analysts have a consensus price target of $1.50.
    Boxlight Corporation (BOXL), a Communication Equipment company, rose about 7.23% at $1.78 in pre-market trading Thursday. The firm recently confirmed that they are the recipients of three THE Journal’s Best New EdTech Product Awards.
    Regulus Therapeutics Inc. (RGLS) stock moved up 19.34 percent to $1.07 in the pre-market trading. The company lately announced closing of $19.4 million private placement of equity.
    Before the trading started on December 10, 2020, Sea Limited (SE) is down -3.3% to reach $196.0 after reporting that it proposes to offer 11,000,000 American Depositary Shares, each representing one Class A ordinary share of the Company, in an underwritten public offering. It has been trading in a 52-week range of $35.61 to $207.51.
    Barclays PLC (NYSE: BCS) shares are trading down -3.85% at $7.5 at the time of writing. The firm recently revealed the launch of BARX Book for Equities, a new single-dealer platform developed in partnership with Nasdaq (Nasdaq: NDAQ). Company’s 52-week ranged between $3.41 to $10.22.
    Qualigen Therapeutics Inc. (QLGN) stock moved up 13.85 percent to $4.44 in the pre-market trading. The company recently announced board member Amy Broidrick as EVP, Chief Strategy Officer and named Sidney Emery, Jr. to its board.

  • Early Morning Vibes: 3 Best Performing Stocks Under $3

    Early Morning Vibes: 3 Best Performing Stocks Under $3

    On December 8, American stock exchanges closed at historic highs. The S&P 500 Index climbed 0.28% to 3702 points, the Dow Jones added 0.35%, the NASDAQ rose 0.5%. The purchases spurred hope for fiscal stimulus, as well as the start of the UK vaccine distribution. The health and energy sectors were the top gains, rising 0.73% and 1.57%, respectively. The real estate segment turned out to be an outsider, losing 0.5%.

    Corporate news

    Tesla (TSLA: + 1.3%) announced a $ 5 billion additional share issue.

    Productivity software maker Smartsheet (SMAR: + 11%) reported strong quarterly results and improved management forecasts.

    Apparel retailer Stitch Fix (SFIX: + 39%) posted a good quarterly report, with a pleasant surprise for investors the company’s profit at a consensus loss.

    Today, world stock markets are showing mostly positive dynamics. The likelihood of accepting an economic aid package is increasing. The day before, Treasury Secretary Stephen Mnuchin presented House Speaker Nancy Pelosi a $ 916 billion economic support bill. Unlike the bipartisan stimulus package last week, the bill provides for a one-time payment of $ 600 to each citizen instead of $ 300 weekly in addition to the unemployment. Republican leaders have already expressed support for Mnuchin’s bill. We believe that the congressmen have not yet been so close to a compromise in the past few months, and this is encouraging.

    Another supportive factor was a report released by the FDA that the Pfizer / BioNTech anticancer vaccine is completely safe and highly effective. The probability of its approval on December 10 is close to 100%, and on the 11th, the distribution of the drug in the United States may begin. We estimate the risk that the pharmaceutical giant will face difficulties in mass production of the vaccine as minimal, although not zero.

    Today Top Movers Under $3

    Cinedigm Corp (CIDM) is up 50.35% at $1.30 in early morning on Wednesday after

    Spherex revealed a strategic alliance with Cinedigm (NASDAQ: CIDM) to drive Cinedigm’s global growth.

    Usio Inc (USIO) is up 38.80% in Wednesday’s premarket session after reporting that it has entered into a non-binding Letter of Intent (LOI) to acquire the assets of Information Management Solutions, LLC (IMS).

    Recon Technology Ltd (RCON) was taking the aerial route in the after-market session as it surged 95.8% to $2.82, after a China-based independent solutions integrator in the oilfield service and environmental protection, electric power, and coal chemical industries, today announced its financial results for the fiscal year 2020.

    Top Upgrades & Downgrades

    JP Morgan turned bullish on Array Technologies Inc. (ARRY), upgrading the stock to “Overweight” and assigning a $41.0 price target.

    Community Trust Bancorp Inc. (CTBI) has won the favor of Piper Sandler’s equity research team. The firm upgraded the shares from Neutral to Overweight.

    Earlier Wednesday JP Morgan reduced its rating on Bloom Energy Corporation (BE) stock to Neutral from Overweight and assigned the price target to $26.0. With shares trading at around $30.59, the Wall Street firm thinks Bloom Energy Corporation’s stock could decline more than -62.5%.

    DZ Bank analysts reduced their investment ratings, saying in research reports covered by the media that its rating for American Express Company (AXP) has been changed to Hold from Buy and the new price target is set at $128.0.

    Analysts at KeyBanc downgraded Talos Energy Inc. (TALO)‘s stock to Sector Weight from Overweight Wednesday.

    Latest Insider Activity

    Freeport-McMoRan Inc. (FCX) Vice Chairman, President & CEO ADKERSON RICHARD C announced the sale of shares taking place on Dec 04 at $25.17 for some 467,887 shares. The total came to more than $11.78 million.

    Discovery Inc. (DISCA) Director LOWE KENNETH W sold on Dec 04 a total 1,202,403 shares at $25.22 on average. The insider’s sale generated proceeds of almost $2.32 million.

    Regulus Therapeutics Inc. (RGLS) 10% Owner Sonsini Peter W. declared the purchase of shares taking place on Dec 04 at $0.62 for some 4,398,602 shares. The transaction amount was around $2.74 million.

    Hepion Pharmaceuticals Inc. (HEPA) CEO and Director Foster Robert T bought on Dec 08 a total 25,259 shares at $1.58 on average. The purchase cost the insider an estimated $39,418.

    Earnings To Watch Today

    Top US earnings releases scheduled for today include Asana Inc. (NYSE:ASAN). It will announce its Oct 2020 financial results. The company is expected to report earnings of -$0.37 per share from revenues of $54.14M in the three-month period.

    Analysts expect Mesa Air Group Inc. (NASDAQ:MESA) to report a net income (adjusted) of -$0.02 per share, when the bank releases its quarterly results shortly. Revenue for the fiscal quarter ended Sep 2020 is predicted to come in at $92.95M.

    Adobe Inc. (ADBE), due to announce earnings after the market closes today, is expected to report earnings of $2.66 per share from revenues of $3.36B recently concluded three-month period.

  • 15 Trending Stocks in Biotechnology Industry

    15 Trending Stocks in Biotechnology Industry

    This year, biotech companies on the stock exchange have skyrocketed. This is no surprise since biotech firms are the leaders in the battle against the coronavirus pandemic. Even with Pfizer’s first vaccine in the UK, investors and pharmaceutical companies are well aware that the race is far ahead.
    Other diseases should not be ignored apart from coronavirus vaccines. The biotech sector is also creating headlines and innovating in areas linked to dementia, cancer, hereditary disorders, etc. Given the above, buyers are probably faced with the difficulty of choosing the best ones to purchase.

    Curis Inc. (NASDAQ:CRIS) shares were trading up 354.86% at $6.55 at the time of writing on Tuesday following announcement of proposed public offering of common stock.

    Curis Inc. (NASDAQ:CRIS) share price went from a low point around $0.62 to briefly over $3.59 in past 52 weeks, though shares have since pulled back to $6.55. CRIS market cap has remained high, hitting $409.70M at the time of writing, giving it price-to-sales ratio of more than 30.

    If we look at the recent analyst rating CRIS, Laidlaw initiated coverage on CRISshares with a Buy rating.

    Lexicon Pharmaceuticals Inc. (LXRX) last closed at $3.08, in a 52-week range of $1.03 to $5.33. Analysts have a consensus price target of $2.37. On November 17, 2020, the firmreported that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.

    IGM Biosciences Inc. (IGMS) stock soar by 57.75% to $115.03 after declaringpricing of upsized $200 million public offering. The most recent rating by Robert W. Baird, on July 17, 2020, is at an Outperform.

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Shares headed rising, higher as much as 29.44%. The company will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) The most recent rating by Oppenheimer, on June 27, 2019, is at an Outperform.

    Oncternal Therapeutics Inc. (NASDAQ:ONCT) rose 27.64% after gaining more than $1.1 on Tuesday after reporting updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial.

    Proteostasis Therapeutics Inc. (PTI) last closed at $1.23, in a 52-week range of $0.87 to $4.72. The firm reported on November 16, 2020. a net loss of approximately $8.2 million for the three months ended September 30, 2020, as compared to a net loss of $12.8 million for the same period in the prior year.

    InflaRx N.V. (IFRX) stock soar by 18.27% to $4.79. The most recent rating by SVB Leerink, on November 06, 2020, is at an Outperform.

    Syros Pharmaceuticals Inc. (NASDAQ:SYRS) Shares headed rising, higher as much as 17.47% after closing $90.5 million strategic financing. The most recent rating by H.C. Wainwright, on November 04, 2020, is at a Buy.

    Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) rose 16.28% after gaining more than $0.28 on Tuesday.

    Ampio Pharmaceuticals Inc. (AMPE) last closed at $1.35, in a 52-week range of $0.31 to $1.39. The firm recently revealed that it will conduct its annual meeting in a virtual format only on December 12, 2020 at 9:00 am MST.

    Regulus Therapeutics Inc. (RGLS)stock soar by 15.19% to $0.93 following the closing of $19.4 million private placement of equity. The most recent rating by B. Riley FBR Inc., on March 28, 2018, is at a Neutral.

    Cancer Genetics Inc. (NASDAQ:CGIX) Shares headed rising, higher as much as 14.79%. The most recent rating by Maxim Group, on December 07, 2017, is at a Buy.

    Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) fall -11.85% after losing more than -$1.85 on Tuesday. The healthcare firm lately declared pricing of $70 million public offering of common stock, which is expected to close on or about December 10, 2020.

    iBio Inc. (IBIO) last closed at $1.31, in a 52-week range of $0.19 to $7.45 after declaring pricing of $35 million public offering of common stock. Analysts have a consensus price target of $2.00.

    Vaccinex Inc. (VCNX) stock soar by 14.08% to $2.35. The most recent rating by BTIG Research, on September 23, 2020, is at a Neutral.